ArticleBMC endocrine disorders2025
Association between serum uric acid to creatinine ratio with metabolic profile in subjects with non-alcoholic fatty liver disease (NAFLD).
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition strongly linked with metabolic syndrome components. The serum uric acid to creatinine (SUA/Cr) ratio has recently emerged as a potential biomarker of metabolic dysfunction. However, its clinical relevance in individuals with NAFLD remains underexplored. The objectives of the current research was to investigate the association between the SUA/Cr ratio and metabolic risk factors in adults diagnosed with NAFLD.
methodsThis cross-sectional study included 226 adults with ultrasonography-confirmed NAFLD (grades 1 and 2). Participants were categorized into tertiles based on their SUA/Cr ratio. Anthropometric indices, biochemical parameters (lipid profile, liver enzymes, glucose), and lifestyle factors were assessed. Differences across SUA/Cr tertiles were analyzed using ANOVA and general linear models adjusted for confounders.
resultsHigher SUA/Cr tertiles were associated with significantly elevated total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels (p = 0.011 and p < 0.001, respectively), and higher alanine aminotransferase (ALT) (p = 0.010), indicating hepatic injury. Central obesity indices (waist circumference and waist-to-hip ratio) increased significantly across tertiles (p = 0.023 and p = 0.025, respectively), although BMI did not. SUA/Cr was not significantly associated with fasting blood glucose or triglycerides. These findings suggest a strong association between elevated SUA/Cr and an unfavorable metabolic and hepatic profile in NAFLD patients.
conclusionThe SUA/Cr ratio is a simple, non-invasive biomarker associated with dyslipidemia, liver enzyme elevation, and central obesity in NAFLD individuals. It may serve as a practical tool for early risk stratification and metabolic monitoring in this high-risk population. Further longitudinal studies are warranted to validate its role in NAFLD progression. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.